Innoviva, Inc engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a long-acting beta2 agonist (LABA), vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate (FF); ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA and LABA.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone650-238-9600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$261 million
Profitability
Miscellaneous
Employees6
Next Earnings Date10/30/2019 (Estimated)
OptionableOptionable
Innoviva (NASDAQ:INVA) Frequently Asked Questions
What is Innoviva's stock symbol?
Innoviva trades on the NASDAQ under the ticker symbol "INVA."
How were Innoviva's earnings last quarter?
Innoviva Inc (NASDAQ:INVA) issued its earnings results on Wednesday, July, 24th. The biotechnology company reported $0.34 EPS for the quarter, missing the consensus estimate of $0.43 by $0.09. The biotechnology company earned $64.11 million during the quarter. Innoviva had a return on equity of 307.49% and a net margin of 146.60%. View Innoviva's Earnings History.
When is Innoviva's next earnings date?
Has Innoviva been receiving favorable news coverage?
Headlines about INVA stock have been trending positive recently, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Innoviva earned a media sentiment score of 2.5 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the stock's share price in the next several days. View News Stories for Innoviva.
Are investors shorting Innoviva?
Innoviva saw a decrease in short interest in July. As of July 31st, there was short interest totalling 12,481,300 shares, a decrease of 11.3% from the June 30th total of 14,071,700 shares. Based on an average daily volume of 882,300 shares, the short-interest ratio is presently 14.1 days. Currently, 18.8% of the company's stock are sold short. View Innoviva's Current Options Chain.
Who are some of Innoviva's key competitors?
Some companies that are related to Innoviva include GW Pharmaceuticals PLC- (GWPH), ACADIA Pharmaceuticals (ACAD), Blueprint Medicines (BPMC), FibroGen (FGEN), Allakos (ALLK), Mirati Therapeutics (MRTX), United Therapeutics (UTHR), Alkermes (ALKS), Ultragenyx Pharmaceutical (RARE), BridgeBio Pharma (BBIO), Evotec (EVTCY), Arrowhead Pharmaceuticals (ARWR), Nektar Therapeutics (NKTR), Taro Pharmaceutical Industries (TARO) and Arena Pharmaceuticals (ARNA).
What other stocks do shareholders of Innoviva own?
Who are Innoviva's key executives?
Innoviva's management team includes the folowing people:
- Mr. Geoffrey Hulme, Interim Principal Exec. Officer (Age 52)
- Ms. Marianne Zhen CPA, Chief Accounting Officer (Age 50)
- Mr. Jeffrey A. Hagenah Ph.D., Chief Patent Counsel and VP
- Dr. Kevin Kwok, Head of Talent Acquisition & Strategy
Who are Innoviva's major shareholders?
Innoviva's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (11.44%), Vanguard Group Inc. (7.02%), Renaissance Technologies LLC (6.96%), LSV Asset Management (2.96%), Man Group plc (2.10%) and D. E. Shaw & Co. Inc. (1.93%). Company insiders that own Innoviva stock include Eric Desparbes, Geoffrey Hulme, George B Abercrombie, George Bickerstaff, Marianne Zhen, Michael W Aguiar and Theodore J Jr Witek. View Institutional Ownership Trends for Innoviva.
Which institutional investors are selling Innoviva stock?
INVA stock was sold by a variety of institutional investors in the last quarter, including Nomura Holdings Inc., Victory Capital Management Inc., WINTON GROUP Ltd, Invesco Ltd., Connor Clark & Lunn Investment Management Ltd., Pictet Asset Management Ltd., Pictet Asset Management Ltd. and Acadian Asset Management LLC. View Insider Buying and Selling for Innoviva.
Which institutional investors are buying Innoviva stock?
INVA stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Nuveen Asset Management LLC, Marshall Wace LLP, LSV Asset Management, Man Group plc, JPMorgan Chase & Co., Wells Fargo & Company MN and Balyasny Asset Management LLC. Company insiders that have bought Innoviva stock in the last two years include Geoffrey Hulme and George Bickerstaff. View Insider Buying and Selling for Innoviva.
How do I buy shares of Innoviva?
Shares of INVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Innoviva's stock price today?
One share of INVA stock can currently be purchased for approximately $11.57.
How big of a company is Innoviva?
Innoviva has a market capitalization of $1.17 billion and generates $261 million in revenue each year. The biotechnology company earns $395.05 million in net income (profit) each year or $3.53 on an earnings per share basis. Innoviva employs 6 workers across the globe.View Additional Information About Innoviva.
What is Innoviva's official website?
How can I contact Innoviva?
Innoviva's mailing address is 2000 SIERRA POINT PARKWAY SUITE 500, BRISBANE CA, 94005. The biotechnology company can be reached via phone at 650-238-9600 or via email at [email protected]
MarketBeat Community Rating for Innoviva (NASDAQ INVA)
MarketBeat's community ratings are surveys of what our community members think about Innoviva and other stocks. Vote "Outperform" if you believe INVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
